IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1548
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.8B
Paulus Stoffels
Galapagos NV engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.
Headcount
1.3K
HQ Base
2800 MECHELEN,
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GLPG GALAPAGOS NV | 53 | 38 | 33 | 57 | 14.6x | - | 10.2% | 7.2% | 113.1% | -42.6% | 26.9% | 7.6% | 0.0% | 0.0x | $1.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
GALAPAGOS NV (GLPG) receives a "Hold" rating with a composite score of 52.9/100. It ranks #1548 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Paulus Stoffels
Chief Executive Officer
Labor Force
1,310
38
63
91
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for GLPG
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Conservative, efficient capex — capital discipline signals management quality
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for GLPG.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 38 | 15 | +23ALPHA |
| MOMENTUM | 57 | 48 | +9ALPHA |
| VALUATION | 33 | 13 | +20ALPHA |
| INVESTMENT | 63 | 98 | -35DRAG |
| STABILITY | 91 | 95 | -4NEUTRAL |
| SHORT INT | 48 | 47 | +1NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 10.2% (sector -2.5%)
GM 113% vs sector 43%, OM -43% vs sector 1%
Capital turnover N/A, R&D intensity 121.7%
Rev growth 8%, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns GALAPAGOS NV a Hold rating, with a composite score of 52.9/100 and 3 out of 5 stars. Ranked #1548 of 7,333 stocks, GLPG presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
GLPG's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 10.2% (sector avg: -2.5%), gross margins of 113.1% (sector avg: 42.5%), net margins of 26.9% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 33/100, GLPG appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 14.61x, a P/B ratio of 0.74x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
GLPG shows a solid investment score of 63/100, reflecting measured but productive capital allocation. Key growth metrics include revenue growth of 7.6% vs. a sector average of 5.9% and a return on assets of 7.2% (sector: -0.1%). This suggests the company is investing at an appropriate level to sustain growth without overextending its balance sheet.
GLPG demonstrates moderate momentum with a score of 57/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 7.6% year-over-year, while a beta of 0.41 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
GALAPAGOS NV earns an excellent stability score of 91/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.41 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
The short interest score of 48/100 for GLPG suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include small-cap liquidity risk. With a $1.8B market cap (small-cap), GALAPAGOS NV may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
GALAPAGOS NV is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1548 of 7,333 overall (79th percentile). Key comparisons include ROE of 10.2% exceeding the -2.5% sector median and operating margins of -42.6% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GLPG currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (91) vs Value (33) — closing this gap could shift the rating.
ROE 513% BELOW SECTOR MEDIAN
Gross Margin 166% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 3400% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate GALAPAGOS NV (GLPG) as a Hold with a composite score of 52.9/100 at a current price of $34.45. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in stability (91th percentile) and investment (63th percentile), which together account for the majority of the composite score. Offsetting weakness in value (33th percentile) and quality (38th percentile) tempers our overall conviction. We assign a Narrow Moat rating (43/100), Low uncertainty, and Standard capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
GALAPAGOS NV holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.9/100 places it at rank #1548 in our full 7,333-stock universe. At $1.8B in market capitalization, GALAPAGOS NV is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 8%, though momentum at the 57th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 113% (+70.6pp vs sector) narrow to operating margins of -43% (-43.9pp vs sector) and net margins of 26.9%, yielding a gross-to-net conversion rate of 24%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $34.45, GALAPAGOS NV is trading at a premium to fundamental value. Our value factor score of 33/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 14.6x (a 34% discount to the sector median of 22.3x), P/B of 0.7x, P/S of 1.9x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 113% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Even high-quality stocks face risks from valuation compression, competitive disruption, or macro shocks that are difficult to quantify in advance.
We assign a Low uncertainty rating to GALAPAGOS NV. The company exhibits strong financial stability with a beta of 0.41, conservative leverage (0% D/E), and a stability factor in the 91th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.41 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 91th percentile and quality factor at the 38th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 113% provide a buffer against cost pressures; conservative leverage (0% D/E) limits balance sheet risk; above-average stability (91th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate GALAPAGOS NV's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 10.2%, and the balance sheet is managed within acceptable parameters (D/E: 0%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; GALAPAGOS NV falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, GALAPAGOS NV receives a Hold rating with a composite score of 52.9/100 (rank #1548 of 7,333). Our quantitative framework assigns a Narrow Moat (43/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 56/100.
Our analysis supports a neutral stance on GALAPAGOS NV. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign GALAPAGOS NV a Narrow Moat rating with a composite moat score of 43/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that GALAPAGOS NV can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 13/20.
The strongest moat sources are margin superiority (13/20) and reinvestment efficiency (9.9/20). GM 113% vs sector 43%, OM -43% vs sector 1%. Capital turnover N/A, R&D intensity 121.7%. These pillars form the core of GALAPAGOS NV's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (4.3/20) and growth durability (7.2/20). ROE proxy 10.2% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect GALAPAGOS NV's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 113% providing a solid profitability foundation, moderate revenue growth of 8%. The margin cascade from 113% gross to -43% operating to 26.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 38th percentile.
The margin profile shows gross margins of 113%, operating margins of -43%, net margins of 26.9%. Return metrics include ROE of 10.2% and ROA of 7.2%. Relative to the Manufacturing sector, gross margins are 70.6 percentage points above the sector median of 43%, and ROE of 10.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of 8%. The sector median D/E is 0%, putting GALAPAGOS NV in a relatively stronger balance sheet position. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
Above 50MA
37.18%
Net New Highs
+51081

About GALAPAGOS NV Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also com
Galapagos (NASDAQ:GLPG) reported quarterly earnings of $13.82 per share. This is a 4506 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $1.049

U.S. stock futures were mixed on Tuesday following Monday's rally that saw the Dow Jones jump nearly 600 points to an all-time high, driven by geopolitical developments in Venezuela. Key movers include CoreWeave rising on Nvidia partnership plans, Vistra gaining on a $4.7 billion acquisition, and Microchip Technology advancing on better-than-expected guidance. Treasury yields held steady at 4.17% for the 10-year bond, with markets pricing in an 83.9% probability of unchanged Fed rates in January.
Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell therapy activities. Management emphasized that the company ended 2025 with roughly €3 billion in cash,
Galapagos (GLPG) is scheduled to announce Q4 earnings results on Monday, February 23rd, before market open. The consensus EPS Estimate is $1.34 (+19.6% Y/Y) and